Literature DB >> 8585554

Trends in antimicrobial susceptibility of bacterial pathogens of the respiratory tract.

G V Doern1.   

Abstract

Rates of antimicrobial resistance have been increasing in bacteria responsible for community-acquired lower respiratory tract infections in the United States. Nearly 100% of clinical isolates of Moraxella catarrhalis now produce beta-lactamase, an enzyme that renders this pathogen resistant to such agents as penicillin, ampicillin, and amoxicillin. However, this organism remains nearly uniformly susceptible to alternative oral antimicrobials, such as cephalosporins, macrolides, tetracyclines, beta-lactamase inhibitor combinations, and the combination of trimethoprim/sulfamethoxazole. The susceptibility of M. catarrhalis to these agents is not expected to change markedly in the next few years. A linear increase in the prevalence of beta-lactamase-mediated ampicillin resistance has been evident among isolates of nontypeable Haemophilus influenzae during the past decade in the United States. By the year 2000, 45-50% of isolates are likely to produce beta-lactamase. Although the susceptibility of this organism to alternative oral antimicrobials varies, rates of resistance to cefuroxime axetil, cefpodoxime, cefixime, azithromycin, and perhaps clarithromycin remain < 1%. The rate of penicillin resistance among isolates of Streptococcus pneumoniae, which has increased steadily in recent years, currently stands at approximately 25% in the United States and will likely reach 40-50% during the next 5-10 years. Because of cross-resistance, in general all beta-lactam antimicrobials have reduced activity against penicillin-resistant strains of S. pneumoniae. A 1994-1995 survey found that 3.4% of S. pneumoniae isolates were highly resistant to cefotaxime, and 4-8% were resistant to chloramphenicol, tetracycline, and the macrolides. Resistance to these antimicrobials has usually followed the emergence of penicillin resistance in other countries. Therefore, S. pneumoniae resistance to these drugs is expected to increase markedly during the next few years in the United States.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8585554     DOI: 10.1016/s0002-9343(99)80303-9

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  16 in total

Review 1.  Clinical use of cefuroxime in paediatric community-acquired pneumonia.

Authors:  C Olivier
Journal:  Paediatr Drugs       Date:  2000 Sep-Oct       Impact factor: 3.022

2.  A 5-year surveillance study of 44,691 isolates of Haemophilus influenzae project Beta-Alert 1993-1997.

Authors:  A Derecola; D L Butler; R L Kaplan; L A Miller; J A Poupard
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

Review 3.  The System of Objectified Judgement Analysis (SOJA). A tool in rational drug selection for formulary inclusion.

Authors:  R Janknegt; A Steenhoek
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

4.  Pharmacokinetics of ciprofloxacin as a tool to optimise dosage schedules in community patients.

Authors:  M Dolores Sánchez Navarro; Carlos Coloma Milano; Aránzazu Zarzuelo Castañeda; M Luisa Sayalero Marinero; Amparo Sánchez-Navarro
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 5.  Antibacterial use in community practice: assessing quantity, indications and appropriateness, and relationship to the development of antibacterial resistance.

Authors:  A G Carrie; G G Zhanel
Journal:  Drugs       Date:  1999-06       Impact factor: 9.546

6.  Acute exacerbations of chronic bronchitis: a pharmacoeconomic review of antibacterial use.

Authors:  Stephen Morris; Pippa Anderson; Debra E Irwin
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

7.  Prevention of Pneumococcal Meningitis.

Authors:  Tina Q. Tan
Journal:  Curr Infect Dis Rep       Date:  2002-08       Impact factor: 3.725

Review 8.  Antibiotic-resistant Streptococcus pneumoniae. Implications for medical practice.

Authors:  E E Wang; J D Kellner; S Arnold
Journal:  Can Fam Physician       Date:  1998-09       Impact factor: 3.275

Review 9.  Cefuroxime axetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  C M Perry; R N Brogden
Journal:  Drugs       Date:  1996-07       Impact factor: 9.546

10.  Effectiveness and safety of short vs. long duration of antibiotic therapy for acute bacterial sinusitis: a meta-analysis of randomized trials.

Authors:  Matthew E Falagas; Drosos E Karageorgopoulos; Alexandros P Grammatikos; Dimitrios K Matthaiou
Journal:  Br J Clin Pharmacol       Date:  2008-09-19       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.